ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_1/article-pS-1.xmlNCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_1/article-pS-1.pdf2026-04-18NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapyhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-p133.xmlNCCN Guidelines and the International Community2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-p133.pdf2026-04-18NCCN Guidelines and the International Communityhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-pxlii.xmlNCCN News2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-pxlii.pdf2026-04-18NCCN Newshttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-plviii.xmlOncology Research Program2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-plviii.pdf2026-04-18Oncology Research Programhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-p136.xmlInvasive Breast Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-p136.pdf2026-04-18Invasive Breast Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-p243.xmlTrastuzumab-Related Cardiac Dysfunction2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-p243.pdf2026-04-18Trastuzumab-Related Cardiac Dysfunctionhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-p233.xmlInflammatory Breast Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-p233.pdf2026-04-18Inflammatory Breast Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-p225.xmlIs There a Need for Axillary Dissection in Breast Cancer?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-p225.pdf2026-04-18Is There a Need for Axillary Dissection in Breast Cancer?https://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-p251.xmlRole of Adjuvant and Posttreatment Exercise Programs in Breast Health2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/2/article-p251.pdf2026-04-18Role of Adjuvant and Posttreatment Exercise Programs in Breast Healthhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_2/article-pS-1.xmlNCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_2/article-pS-1.pdf2026-04-18NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemiahttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-36.xmlSafe and Successful Implementation of CPOE for Chemotherapy at a Children's Cancer Center2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-36.pdf2026-04-18Safe and Successful Implementation of CPOE for Chemotherapy at a Children's Cancer Centerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-25.xmlPharmacotherapy for Chronic Myelogenous Leukemia: A Case-Based Approach2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-25.pdf2026-04-18Pharmacotherapy for Chronic Myelogenous Leukemia: A Case-Based Approachhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-13.xmlNew Options for the Management of Castration-Resistant Prostate Cancer: A Case Perspective2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-13.pdf2026-04-18New Options for the Management of Castration-Resistant Prostate Cancer: A Case Perspectivehttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-10.xmlWhere Your Data Is Going and Where It's Been2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-10.pdf2026-04-18Where Your Data Is Going and Where It's Beenhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-6.xmlBiosimilars: Approval and Acceptance?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-6.pdf2026-04-18Biosimilars: Approval and Acceptance?https://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pvii.xmlNew NCCN Program Recognizes Organizations Supporting Coverage for Clinical Trials and Appropriate Off-Label Drug Usage2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pvii.pdf2026-04-18New NCCN Program Recognizes Organizations Supporting Coverage for Clinical Trials and Appropriate Off-Label Drug Usagehttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-4.xmlInforming Patients: Translating the NCCN Guidelines2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-4.pdf2026-04-18Informing Patients: Translating the NCCN Guidelineshttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-2.xmlA Quick REMS Update and a Clinical Focus2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-2.pdf2026-04-18A Quick REMS Update and a Clinical Focushttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-1.xmlTake Your Medicine2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-pS-1.pdf2026-04-18Take Your Medicinehttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-px.xmlNCCN Trends2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_3/article-px.pdf2026-04-18NCCN Trends